CD123, CD33, and CLL-1 Combination

The targets CD123, CD33, and CLL-1 are three distinct cell surface molecules, most commonly cited together as therapeutic targets in acute myeloid leukemia (AML) and related hematological malignancies. Dual and triple targeting strategies, employing bispecific antibodies or bicistronic CAR-T therapies, are under clinical investigation to maximize coverage of AML blast and leukemic stem cell populations and minimize therapeutic escape due to antigen loss or variability. However, it is not recommended to return these three distinct molecules together as a single target entity. Each is a unique molecule with specific aliases and biological properties that should be mapped and annotated individually for structured data extraction, despite their common use in combination therapeutic approaches.

Combined CAR-T cell-mediated cytotoxicity and/or bispecific antibody-induced T-cell redirection, aiming to maximize therapeutic coverage and minimize escape mechanisms in AML by simultaneously targeting multiple distinct antigens.